Herein provided are dosage forms (variously referred to as "formulations") comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
申请公布号
US8461187(B2)
申请公布日期
2013.06.11
申请号
US20050629016
申请日期
2005.06.01
申请人
TANEJA RAJNEESH;VAKILYNEJAD MAJID;TAKEDA PHARMACEUTICALS U.S.A., INC.
